問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Infectious Disease

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

National Taiwan University Cancer Center

Division of General Internal Medicine

更新時間：2025-03-04

余忠仁Yu, Chong-Jen
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years 1 個月

Recruiting Trial

169Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

余忠仁

List

358Cases

2025-11-01 - 2033-12-31

Phase III

Not yet recruiting
A phase III, open-label, randomized, multicenter, parallel-group trial evaluating the efficacy and safety of first-line trastuzumab deruxtecan combined with rilvegostomig or volrustomig versus pembrolizumab plus chemotherapy in locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous NSCLC (DESTINY-Lung07).

  • Condition/Disease

    Locally advanced unresectable or metastatic HER2-overexpressing non-squamous non-small cell lung cancer

  • Test Drug

    Trastuzumab Deruxtecan(AZD4552 DS-8201A)

Participate Sites
9Sites

Recruiting9Sites

2018-12-01 - 2027-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2021-04-01 - 2033-02-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-06-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-08-01 - 2031-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2016-07-01 - 2020-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-04-02 - 2023-12-06

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-12-01 - 2016-11-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2005-07-01 - 2008-07-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2023-03-01 - 2027-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

1 2 3 4 5 36
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB